近日，云南沃森生物技术股份有限公司（以下简称"公司"）收到新型冠状 病毒变异株 mRNA 疫苗（Omicron XBB.1.5），代号：RQ3033（以下简称"本疫 苗"或"RQ3033 疫苗"）的Ⅲ期免疫原性桥接临床研究报告。报告显示，本疫 苗Ⅲ期免疫原性桥接临床试验研究结果全面达到预设目标，具有良好的有效性和 安全性。 RQ3033 疫苗是公司及子公司玉溪沃森生物技术有限公司与上海蓝鹊生物医 药有限公司、复旦大学合作研发的新型冠状病毒变异株 mRNA 疫苗（Omicron XBB.1.5），拥有自主知识产权。 证券代码：300142 证券简称：沃森生物 公告编号：2024-023 云南沃森生物技术股份有限公司 关于新型冠状病毒变异株mRNA疫苗（Omicron XBB.1.5） （代号：RQ3033）Ⅲ期免疫原性桥接临床试验 获得临床研究报告的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 RQ3033 疫苗现已完成支持药品注册申请上市的主要研究工作。根据国家药 品注册管理办法规定的程序，本疫苗药品注册申请上市需经过技术审评、临床试 验注册现场核查、 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the fiscal year, representing a 20% growth compared to the previous year[123]. - The company achieved a revenue growth of 20% compared to the previous year, driven by increased demand for its vaccines[6]. - The company's operating revenue for 2023 was ¥4,113,772,327.17, a decrease of 19.12% compared to ¥5,086,445,195.10 in 2022[13]. - The total revenue for 2023 was approximately ¥4.11 billion, a decrease of 19.12% compared to ¥5.09 billion in 2022[50]. - The revenue from self-developed vaccines was approximately ¥4.08 billion, accounting for 99.12% of total revenue, also down by 19.02% from ¥5.04 billion in 2022[50]. - The company reported a net profit margin of 18%, reflecting improved operational efficiency and cost management strategies[123]. - The net profit attributable to shareholders for 2023 was ¥419,390,211.20, down 42.44% from ¥728,652,009.34 in 2022[13]. - The net profit after deducting non-recurring gains and losses was ¥573,585,030.87, a decrease of 33.95% from ¥859,124,544.51 in 2022[13]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year 2023, representing a growth of 15% year-over-year[115]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.10 CNY per 10 shares (including tax) to all shareholders[2]. - The board of directors approved a dividend payout of 0.5 CNY per share, signaling confidence in the company's financial health and future growth prospects[123]. - The total cash dividend amount, including other methods, is 88,191,251.85 yuan, which accounts for 100% of the total profit distribution[142]. - The profit distribution plan for 2023 is subject to approval at the annual shareholders' meeting, with implementation expected within two months post-approval[143]. - The company has committed to a profit distribution policy that emphasizes reasonable returns to investors, with a minimum cash distribution of 30% of the average distributable profit over the last three years if conditions are met[186]. Research and Development - The company has invested 100 million CNY in research and development for new vaccine technologies in 2023[6]. - The company’s R&D investment in 2023 amounted to approximately ¥910.61 million, representing 22.14% of its operating revenue, an increase from 20.70% in 2022[65]. - The company is conducting clinical research on multiple vaccines, including a recombinant HPV vaccine and various COVID-19 mRNA vaccines, aiming to enhance its technological capabilities and core competitiveness[63]. - The company aims to enhance its vaccine R&D pipeline based on four technology platforms, including mRNA and recombinant adenovirus vaccines, targeting innovative vaccines such as respiratory syncytial virus and combined COVID-19-influenza vaccines over the next 5-10 years[87]. - The company has established advanced technology platforms, including mRNA, bacterial vaccines, and recombinant protein vaccines, to enhance its R&D capabilities[44]. Market Expansion and Strategy - The company is focusing on expanding its market presence and developing new products, including mRNA vaccines for COVID-19 variants[6]. - The company is actively pursuing mergers and acquisitions to enhance its product portfolio and market reach[6]. - The company is actively expanding into overseas markets, particularly in countries along the Belt and Road Initiative, to drive new growth opportunities[22]. - The company is planning to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region within the next two years[123]. - A strategic acquisition of a smaller biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and product portfolio[123]. Compliance and Risk Management - The company has outlined potential risks in its future development and corresponding countermeasures in the management discussion section[2]. - The company is committed to maintaining compliance with national vaccine management laws and regulations to ensure product quality and safety[6]. - The company emphasizes compliance and risk management in its sales processes, both domestically and internationally, to ensure efficient operations[42]. - The company acknowledges increasing policy risks due to heightened regulatory standards in the pharmaceutical industry and is committed to adapting to these changes proactively[92]. - The company has established a comprehensive quality management system to address potential adverse reactions associated with vaccines, ensuring compliance with national regulations[93]. Product Development and Innovation - The company has launched a total of 38,087,785 vaccine doses in 2023, representing a year-on-year increase of 61.17% in batch approvals[33]. - The company is advancing the ACYW135 meningococcal polysaccharide conjugate vaccine, which is currently in Phase III clinical trials[35]. - The new mRNA vaccine for the Omicron XBB.1.5 variant received emergency use approval in December 2023, marking a breakthrough in the company's mRNA vaccine technology[35]. - The company has successfully developed and launched 10 vaccine products, including the 13-valent pneumococcal conjugate vaccine and the bivalent HPV vaccine[45]. - The company is developing a new vaccine laboratory in Yunnan, which is expected to enhance production capabilities[95]. Environmental and Social Responsibility - The company has received environmental approvals for multiple projects, including the industrialization of vaccines and the replacement of coal-fired boilers with gas boilers[166]. - The company has established a comprehensive environmental management system and emergency response plan for environmental incidents[177]. - The company donated a total of 350,000 RMB to the China Women's Development Foundation and 490,000 RMB to the Red Cross Foundation for public health initiatives[182]. - The company provided 204,868 doses of the bivalent HPV vaccine and 14,100 doses of the 23-valent pneumococcal polysaccharide vaccine as part of its social responsibility efforts[182]. - The company emphasizes green, circular, and low-carbon development in its operations, aligning with national carbon neutrality goals[178]. Governance and Shareholder Engagement - The company has established a stable governance structure, ensuring the rights of shareholders, particularly minority shareholders, are protected[98]. - The company conducted 16 investor research sessions during the reporting period, enhancing communication and transparency with investors[101]. - The company has engaged with over 74 institutional investors during recent communications, reflecting strong interest in its growth prospects[96]. - The company has implemented a new system for the management of director and supervisor allowances, effective from April 20, 2023[127]. - The company has a clear organizational structure with defined roles and responsibilities, ensuring effective governance[105]. Financial Health and Assets - The company’s total assets as of December 31, 2023, were reported at 1.5 billion CNY, reflecting a year-on-year increase of 15%[6]. - The total assets at the end of 2023 were ¥15,588,869,273.40, an increase of 1.70% from ¥15,327,991,128.58 at the end of 2022[13]. - Cash and cash equivalents at the end of 2023 amounted to CNY 4,364,534,810.22, representing 28.00% of total assets, an increase from 25.26% at the beginning of the year[69]. - The company has a total of 75 authorized patents and several more pending, reflecting its commitment to innovation and technology development[45]. - The company has established a complete independent personnel management system, ensuring no conflicts of interest with major shareholders[105].

证券代码：300142 证券简称：沃森生物 公告编号：2024-022 云南沃森生物技术股份有限公司 关于举办2023年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）已于 2024 年 3 月 30 日在巨潮资讯网上披露了公司《2023 年年度报告》。为便于广大投资者更加全面 深入地了解公司的经营业绩、发展战略、未来发展规划等情况，公司定于 2024 年 4 月 3 日（星期三）15:00-17:00 在"价值在线"（www.ir-online.cn）举办公司 2023 年度业绩网上说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、业绩说明会召开的时间、地点和方式 传真：0871-68312779 邮箱：ir@walvax.com 五、其他事项 会议召开时间：2024 年 4 月 3 日（星期三）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、公司参加人员 出席本次业绩说明会的公司人员有：公司董事长李云 ...

云南沃森生物技术股份有限公司 内部控制鉴证报告 大信专审字[2024]第 5-00014 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 内部控制鉴证报告 大信专审字[2024]第 5-00014 号 云南沃森生物技术股份有限公司全体股东： 我们接受委托，对云南沃森生物技术股份有限公司(以下简称"贵公司") 2023 年 12 月 31 日与财务报告相关的内部控制有效性的认定进行了鉴证。 一、企业 ...

证券代码：300142 证券简称：沃森生物 公告编号：2024-015 云南沃森生物技术股份有限公司 关于2023年下半年计提信用减值准备、资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）于 2024 年 3 月 29 日 召开第五届董事会第十六次会议和第五届监事会第十四次会议，审议通过了《关 于 2023 年下半年计提信用减值准备、资产减值准备的议案》。根据《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》《企业会计准则》等相关规定的要求，公司及下属子公司对 2023 年度末各类存货、应收账款、其他应收款、应收退货成本、固定资产、在建 工程、长期股权投资、无形资产、金融资产及商誉等资产进行了全面清查，对各 类存货的可变现净值，应收款项回收的可能性，固定资产、在建工程、金融资产 及无形资产等的可变现性进行了充分的评估和分析，认为上述资产中部分资产存 在一定的减值迹象 ...

云南沃森生物技术股份有限公司 非经营性资金占用及其他关联资金 往来情况汇总表的专项审计报告 大信专审字[2024]第 5-00008 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 非经营性资金占用及其他关联资金往来情况汇总表的 专项审计报告 大信专审字[2024]第 5-00008 号 云南沃森生物技术股份有限公司全体股东： 我们接受委托，审计了云南沃森生物技术股份有限公司（以下简称"贵公司"） ...

云南沃森生物技术股份有限公司 2023 年度财务决算报告 云南沃森生物技术股份有限公司 2023 年度财务决算报告 云南沃森生物技术股份有限公司（以下简称"沃森生物"或"公司"）2023 年 12 月 31 日的合并及母公司资产负债表、合并及母公司利润表、合并及母公司现金流 量表、合并及母公司股东权益变动表和财务报表附注已经大信会计师事务所（特殊普 通合伙）进行审计，并出具标准的无保留意见审计报告（大信审字[2024]第 5-00004 号）。 2023 年度，公司实现营业收入 411,377.23 万元，较上年同期减少 19.12%；净 利润 51,132.51 万元，较上年同期减少 45.50%；归属于母公司所有者的净利润 41,939.02 万元，较上年同期减少 42.44%。现将公司 2023 年度财务决算（合并口径） 的相关情况报告如下： 一、主要资产情况 单位：人民币元 | 序号 | 项目 | 2023 年 12 月 31 日 | 2023 年 1 月 1 日 | 增减变动额 | 变动幅度 | | --- | --- | --- | --- | --- | --- | | 1 | 预付款项 | 1 ...

云南沃森生物技术股份有限公司 关联交易决策制度 云南沃森生物技术股份有限公司 关联交易决策制度 第一章 总则 公司关联人包括关联法人和关联自然人。 1 第一条 为规范公司的关联交易，保护公司、股东和债权人的合法权益，保证公司关 联交易决策行为的合规性，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"）、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》《深圳证券交易所上市公司自律监管指引第7号——交易与关联 交易》等法律法规及规范性文件以及《云南沃森生物技术股份有限公司章程》 （以下简称"《公司章程》"）的规定，特制定本制度（以下简称"本制度"）。 第二条 在本制度中，关联交易是指公司或其控股子公司与公司关联人之间发生的转 移资源或义务的事项。 第三条 具有以下情形之一的法人或者其他组织，为公司的关联法人： (一) 直接或间接地控制公司的法人或者其他组织； (二) 由前项所述法人直接或间接控制的除公司及其控股子公司以外的法人 或者其他组织； (三) 由本制度第四条所列的关联自然人直接或间接控制的、或担任董事（独 立 ...

华创证券有限责任公司 关于云南沃森生物技术股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》、《深圳证券交易所创业板股票上市规则》以及《上市公司监管指引第 2号——上市公司募集资金管理和使用的监管要求》等相关法规的要求，华创证 券有限责任公司（以下简称"华创证券"）作为云南沃森生物技术股份有限公司 （以下简称"公司"、"上市公司"、"沃森生物"）发行股份购买资产并募集 配套资金独立财务顾问，对上市公司2016年度向3名特定投资者发行股份所募集 资金的存放和使用情况进行了专项核查，对沃森生物出具的《云南沃森生物技术 股份有限公司2023年度募集资金存放与实际使用情况专项报告》和大信会计师事 务所（特殊普通合伙）出具的《云南沃森生物技术股份有限公司募集资金存放与 实际使用情况审核报告》（大信专审字[2024] 第5-00007号）进行了核查，具体 情况如下： 一、募集资金的存放、使用及专户余额情况 （一）募集资金基本情况 1、募集资金金额及到位情况 经中国证券监督管理委员会《关于核准云南沃森生物技术股份有限公司向新 余方略 ...

WALVAX 沃森生物® 2023年度可持续发展 暨ESG和社会责任报告 云 南 沃 森 生 物 技 术 股 份 有 限 公 司 绿色运营 环境友好 95 n in in | 2 | | | --- | --- | | 高效治理 稳健发展 | | | 党建强基铸魂 | 19 | | 强化公司治理 | 21 | | 提升发展动力 | 25 | | 恪守商业道德 | 27 | | 信息安全与隐私保护 | 31 | in 社区共建 健康共享 63 助力健康可及 65 76 产业协同共赢 77 倾情暖心公益 | | | 创新驱动 赋能健康 二 | | | --- | --- | --- | --- | | | | 创新引领未来 | 37 | | 董事长致辞 | 01 | 坚持质量优先 | 45 | | 关于沃森 | 03 | 专业客户服务 | 53 | | 可持续发展管理策略 | 11 | 可持续供应链 | 57 | 以人为本 活力职场 7 9 多元包容职场 81 85 激发人才活力 职业健康与安全 92 | 完善环境管理 | 97 | | --- | --- | | 应对气候变化 | 99 | | 资源利用与循环经 ...